EDAP TMS will discuss Q2 2025 financial results in a conference call on August 28th at 8:30am EDT.
Quiver AI Summary
EDAP TMS SA, a leader in robotic energy-based therapies, has announced that it will release its financial results for the second quarter of 2025 on Thursday, August 28th, before market opening. A conference call and webcast will take place the same day at 8:30 am EDT, featuring CEO Ryan Rhodes, CFO Ken Mobeck, and Chief Accounting Officer François Dietsch. The press release includes dial-in details for domestic and international participants, along with a passcode and a link for webcast registration. EDAP TMS specializes in developing minimally invasive medical devices utilizing ultrasound technology, notably the Focal One® system for prostate cancer treatment, with potential applications beyond this indication. Further information about the company can be found on its website.
Potential Positives
- The scheduled conference call and webcast demonstrate the company's commitment to transparency and keeping investors informed about financial performance.
- EDAP TMS SA is positioned as a leader in the innovative field of robotic energy-based therapies, which is likely to attract interest from potential investors.
- The upcoming release of second-quarter financial results could highlight positive growth or advancements in the company's technology and services.
Potential Negatives
- The press release does not provide any information about the company's financial performance or expectations, which could raise concerns among investors regarding transparency and future growth prospects.
- The lack of specific details regarding the upcoming financial results may lead to uncertainty in the market, potentially affecting investor confidence.
- Notable absence of updates on product developments or clinical results could suggest stagnation in innovation or market competitiveness, impacting the company's image as a leader in the field.
FAQ
When will EDAP TMS SA release its Q2 2025 financial results?
EDAP TMS SA will release its financial results on Thursday, August 28th, 2025, before the markets open.
What time is the conference call scheduled for?
The conference call is scheduled for 8:30 am EDT on August 28th, 2025.
Who will participate in the conference call?
The conference call will feature Ryan Rhodes, Ken Mobeck, and François Dietsch.
How can I access the webcast for the conference call?
You can access the webcast at https://viavid.webcasts.com/starthere.jsp?ei=1726716&tp_key=220919ac3d.
What does EDAP TMS SA specialize in?
EDAP TMS SA specializes in robotic energy-based therapies and minimally invasive medical devices using ultrasound technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EDAP Hedge Fund Activity
We have seen 11 institutional investors add shares of $EDAP stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANQUE TRANSATLANTIQUE SA added 720,499 shares (+7063.7%) to their portfolio in Q1 2025, for an estimated $1,412,178
- ARCHON CAPITAL MANAGEMENT LLC removed 709,074 shares (-72.2%) from their portfolio in Q1 2025, for an estimated $1,389,785
- SCOGGIN MANAGEMENT LP added 350,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $686,000
- ROCK SPRINGS CAPITAL MANAGEMENT LP removed 321,800 shares (-20.2%) from their portfolio in Q1 2025, for an estimated $630,728
- SAGE MOUNTAIN ADVISORS LLC added 100,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $165,000
- MILLENNIUM MANAGEMENT LLC removed 37,630 shares (-76.9%) from their portfolio in Q1 2025, for an estimated $73,754
- SIMPLICITY WEALTH,LLC added 32,548 shares (+inf%) to their portfolio in Q2 2025, for an estimated $53,704
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EDAP Analyst Ratings
Wall Street analysts have issued reports on $EDAP in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 03/28/2025
- Piper Sandler issued a "Overweight" rating on 03/28/2025
To track analyst ratings and price targets for $EDAP, check out Quiver Quantitative's $EDAP forecast page.
$EDAP Price Targets
Multiple analysts have issued price targets for $EDAP recently. We have seen 3 analysts offer price targets for $EDAP in the last 6 months, with a median target of $4.5.
Here are some recent targets:
- Michael Sarcone from Jefferies set a target price of $2.0 on 04/04/2025
- Jason Bednar from Piper Sandler set a target price of $4.5 on 03/28/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $19.0 on 03/28/2025
Full Release
Company to host conference call and webcast on Thursday, August 28 th at 8:30am EDT
AUSTIN, Texas, August 7, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30, 2025, before the markets open on Thursday, August 28 th , 2025.
An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Call Details:
Date: Thursday, August 28 th
Time: 8:30 am EDT
Domestic: 1-800-274-8461
International: 1-203-518-9814
Passcode: EDAP
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1726716&tp_key=220919ac3d
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One ® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/ .
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
[email protected]
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
[email protected]
